Adaptive Biotechnologies (ADPT) Stock May Be Trading At A Premium Following Its 477% Run

Adaptive Biotechnologies has delivered a very large 3 year share price gain, which puts fresh focus on whether the current valuation lines up with the cash the business is expected to generate. With the stock now trading at US$27.37 after a strong run and some recent volatility, the question is how well that price matches an intrinsic value estimate based on its cash flows.

• The share price has climbed by about 4.8x over the past 3 years, so a lot now rides on whether the underlying cash flow profile can support that kind of re-rating.
• The spotlight on clonoSEQ in the new International Myeloma Society cure definition may support expectations for future testing volumes and, in turn, the timing and durability of Adaptive Biotechnologies' potential cash flows.
• What if you looked at Adaptive Biotechnologies through its sales instead? See what Adaptive Biotechnologies's 14.2x P/S says about the price.

For investors, the debate is whether Adaptive Biotechnologies' current share price is adequately backed by its projected cash flows when measured against an intrinsic value estimate using a Discounted Cash Flow model.

If you want more ideas built around cash flow valuation rather than a single stock story, a focused screener of 28 high quality undervalued stocks can be a useful next step in your research.

Is Adaptive Biotechnologies Getting Expensive on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at what Adaptive Biotechnologies might return to shareholders in future cash, then adjusts those amounts back to today. Latest twelve month free cash flow is a loss of $26.74 million, so the whole framework leans heavily on the expectation that the business shifts from burning cash to generating it at scale over the next decade.

Analysts and model estimates imply recovering and then growing free cash flow, with projected yearly figures moving into positive territory and building from there. Despite Adaptive Biotechnologies highlighting clonoSEQ’s role in the new International Myeloma Society cure definition, the DCF outcome still places the estimated intrinsic value meaningfully below the current share price of US$27.37. This suggests the recent excitement around MRD testing may already be well reflected in the valuation. Find out what Adaptive Biotechnologies could be worth using our Discounted Cash Flow (DCF) estimate.

The Adaptive Biotechnologies Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take that valuation puzzle around Adaptive Biotechnologies and spell out which expectations on growth, profitability and earnings would need to play out for the stock to be worth much more or much less than today's price, and they sit on Simply Wall St's Community page. Each Narrative sets out its own fair value assumptions in detail, so you can later compare those building blocks with the actual numbers the company reports over time.

The community runs with the same core facts on Adaptive Biotechnologies, yet one camp sees more upside potential than the other.

Bull case: 22% undervalued

"Analyst consensus points to mid-teens percent price improvements and higher volume from payer contracts and ASP uplift, but coverage and pricing wins are happening faster and with broader scope than expected…"

Discover why this Narrative puts Adaptive Biotechnologies at 22% undervalued.

Bear case: roughly fairly valued

"Increasing pricing pressure or reimbursement risk, while ASPs for clonoSEQ are currently rising due to favorable contracts, recent successes may not be sustainable long term as government or private payer policies can shift…"

Explore why this Narrative puts Adaptive Biotechnologies at roughly fairly valued.

One more piece of the Adaptive Biotechnologies puzzle before you act

Before you lean too hard on any cash flow model for Adaptive Biotechnologies, it is worth asking who is steering the ship and how their rewards line up with long term shareholder outcomes. See who runs Adaptive Biotechnologies and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com